Atogepant

Atogepant
Clinical data
Trade names	Qulipta
Other names	AGN-241689, MK-8031
License data	US DailyMed: Atogepant;
Routes of; administration	By mouth
ATC code	N02CD07 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide;
CAS Number	1374248-81-3;
PubChem CID	72163100;
DrugBank	DB16098;
ChemSpider	59718640;
UNII	7CRV8RR151;
KEGG	D11313;
ChEMBL	ChEMBL3991065;
Chemical and physical data
Formula	C29H23F6N5O3
Molar mass	603.525 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F;
	InChI InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1; Key:QIVUCLWGARAQIO-OLIXTKCUSA-N;

Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.^[1]^[2]

It was approved for medical use in the United States in September 2021.^[1]^[3]

References[]

^ ^a ^b ^c "Qulipta- atogepant tablet". DailyMed. Retrieved 31 October 2021.
^ Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (June 2020). "Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?". Current Opinion in Neurology. 33 (3): 309–315. doi:10.1097/WCO.0000000000000806. PMID 32251023. S2CID 215408433.
^ "FDA Approves Qulipta (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine". AbbVie (Press release). 28 September 2021. Retrieved 29 September 2021 – via PR Newswire.

External links[]

"Atogepant". Drug Information Portal. U.S. National Library of Medicine.

This analgesic-related article is a stub. You can help Wikipedia by .

[Qulipta_FDA_label-1] "Qulipta- atogepant tablet". DailyMed. Retrieved 31 October 2021.

[Moreno-Ajona_2020-2] Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ (June 2020). "Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?". Current Opinion in Neurology. 33 (3): 309–315. doi:10.1097/WCO.0000000000000806. PMID 32251023. S2CID 215408433.

[3] "FDA Approves Qulipta (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine". AbbVie (Press release). 28 September 2021. Retrieved 29 September 2021 – via PR Newswire.

[1]

[2]

[3]